Document Detail

Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis.
MedLine Citation:
PMID:  22847245     Owner:  NLM     Status:  MEDLINE    
The aim of this retrospective study was to examine the predictors of discontinuation of anti-tumor necrosis factor (TNF) therapy due to adverse events in Chinese patients with rheumatoid arthritis (RA). Anti-TNF-related adverse events were recorded and analyzed in 217 consecutive patients with RA followed in our institution from 2003 to 2010. Time to discontinuation of anti-TNF-α therapy was estimated using survival analysis techniques. The anti-TNF agents administered were etanercept in 181 patients and adalimumab in 36 patients. The mean age at diagnosis was 45.2 ± 13.5 years, and mean age at initiation of anti-TNF therapy was 51.8 ± 13.0 years. The mean duration of anti-TNF agent use was 36.0 ± 26.5 months (range, 1.4-87.0; median, 26.4 months). Of the 217 patients, 39 (18.0 %) developed adverse events [etanercept in 34 (18.8 %] and adalimumab in 5 (13.9 %)] during the treatment period (tuberculosis in 5, bacterial infections in 19, virus infection in 7, neuropathy in 3, malignancy in 3, other drug-related events in 1, and appendicitis in 1). In patients with RA, older age (≥55 years) at initiation of anti-TNF therapy [odds ratio (OR), 3.20; 95 % confidence interval (CI), 1.67-6.20; p < 0.001], Cr ≥1.5 mg/dL (OR, 5.72; 95 % CI, 1.17-27.90; p = 0.031), and occurrence of adverse events (OR, 3.82; 95 % CI, 1.75-8.35; p = 0.001) were associated with increased likelihood of discontinuation of anti-TNF treatment. In the present study, a significant proportion (7.8 %, 17/217) of patients with RA discontinued anti-TNF treatment because of adverse events. In the elderly and in patients with renal insufficiency, caution is needed when starting anti-TNF treatment.
Cheng-Tao Yang; Chang-Fu Kuo; Shue-Fen Luo; Kuang-Hui Yu
Related Documents :
17458615 - Prosthetic mesh repair of large and recurrent diaphragmatic hernias.
12802655 - Seroma following endoscopic extraperitoneal inguinal hernioplasty.
17273815 - Comparison of prosthetic mesh repair and tissue repair in the emergency management of i...
2343365 - Recurrent inguinal hernia in relation to ideal body weight.
12466905 - Voiding dysfunction following tvt procedure.
20680245 - Serial dilation reduces graft slippage compared to extraction drilling in anterior cruc...
Publication Detail:
Type:  Journal Article     Date:  2012-07-31
Journal Detail:
Title:  Clinical rheumatology     Volume:  31     ISSN:  1434-9949     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-30     Completed Date:  2013-04-24     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1549-57     Citation Subset:  IM    
Division of Chinese Medicine, Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / adverse effects*
Arthritis, Rheumatoid / drug therapy*,  immunology*
Cohort Studies
Immunoglobulin G / adverse effects*
Middle Aged
Odds Ratio
Receptors, Tumor Necrosis Factor
Retrospective Studies
Rheumatology / methods
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Kinetic Monte Carlo modeling of silicate oligomerization and early gelation†
Next Document:  Improved single-limb balance after total knee arthroplasty.